(CNBS) Amplify Seymour Cannabis - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US0321088546 • Miscellaneous Sector
CNBS: Cannabis, Hemp, Securities, Derivatives, Ecosystem
The Amplify Seymour Cannabis ETF (NYSE ARCA: CNBS) is a targeted exchange-traded fund designed to provide exposure to U.S. companies operating in the cannabis and hemp industries. Under normal market conditions, the fund invests at least 80% of its net assets in securities of U.S. firms that generate 50% or more of their revenue from the cannabis and hemp ecosystem. This includes direct industry participants and companies providing goods and services to the sector. The fund may also invest in derivatives that economically resemble direct holdings in these securities.
As a non-diversified fund, CNBS can allocate a greater proportion of its assets to a smaller number of holdings, which may amplify exposure to sector-specific risks and opportunities. The fund is managed by Amplify Investments LLC, which employs an active approach to select companies poised to benefit from the growth and evolution of the U.S. cannabis and hemp markets.
Based on the provided data, CNBS is currently trading at $19.33, below its 20-day and 50-day moving averages of $20.92 and $21.98, respectively. The 200-day moving average stands at $31.65, indicating a downtrend over the past year. The funds average trading volume over the past 20 days is approximately 50,415 shares, with an average true range (ATR) of 0.71, suggesting moderate volatility. CNBS has total assets under management (AUM) of $68.88 million, reflecting its niche focus within the cannabis sector.
Additional Sources for CNBS ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CNBS ETF Overview
Market Cap in USD | 69m |
Category | Miscellaneous Sector |
TER | 0.75% |
IPO / Inception | 2019-07-15 |
CNBS ETF Ratings
Growth 5y | -84.3% |
Fundamental | - |
Dividend | 72.5% |
Rel. Strength Industry | -55.6 |
Analysts | - |
Fair Price Momentum | 14.59 USD |
Fair Price DCF | - |
CNBS Dividends
Dividend Yield 12m | 40.87% |
Yield on Cost 5y | 14.91% |
Annual Growth 5y | 154.18% |
Payout Consistency | 42.9% |
CNBS Growth Ratios
Growth Correlation 3m | -87.3% |
Growth Correlation 12m | -91.2% |
Growth Correlation 5y | -83% |
CAGR 5y | -23.70% |
CAGR/Max DD 5y | -0.25 |
Sharpe Ratio 12m | -1.12 |
Alpha | -57.04 |
Beta | 0.35 |
Volatility | 74.88% |
Current Volume | 8.3k |
Average Volume 20d | 4.7k |
As of March 09, 2025, the stock is trading at USD 18.56 with a total of 8,280 shares traded.
Over the past week, the price has changed by -5.56%, over one month by -16.42%, over three months by -27.62% and over the past year by -49.69%.
No, based on ValueRay Analyses, Amplify Seymour Cannabis (NYSE ARCA:CNBS) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -84.33 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CNBS as of March 2025 is 14.59. This means that CNBS is currently overvalued and has a potential downside of -21.39%.
Amplify Seymour Cannabis has no consensus analysts rating.
According to ValueRays Forecast Model, CNBS Amplify Seymour Cannabis will be worth about 16.1 in March 2026. The stock is currently trading at 18.56. This means that the stock has a potential downside of -13.09%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 16.1 | -13.1% |